DR-0201 is under clinical development by Dren Bio and currently in Phase I for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase I drugs for Marginal Zone B-cell Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DR-0201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DR-0201 overview
DR-0201 is under development for the treatment of hematologic neoplasms including relapsed or refractory B-cell non-Hodgkin lymphomas including chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large b cell lymphoma (DLBCL), high-grade b-cell lymphoma (HGBCL). The drug candidate is a bispecific antibody developed using proprietary targeted myeloid engager and phagocytosis platform technology. It is administered through intravenous route.
Dren Bio overview
Dren Bio is a biotechnology company that develops protein engineering technologies to expand diseased cells, protein aggregates and agents. The company product pipeline includes DR-01 and DR-02. Its DR-01 products use to kill cells in leukemia, lymphomas and autoimmune diseases by using antibody-mediated killing and DR-02 an antibody-based platform to develop drugs targeting solid tumors, hematologic neoplasms, infectious diseases and protein aggregate diseases. The company operates in the US. Dren Bio is headquartered in Redwood City, California, the US.
For a complete picture of DR-0201’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
